Agios Pharmaceuticals, Inc. AGIO

Mitapivat (PYRUKYND® and AQVESME™) delivered worldwide net revenues of $44.7 million in the second quarter of 2026, compared to $12.5 million in the second quarter of 2025Strong U.S. commercial launch of AQVESME in thalassemia, with 442 cumulative prescriptions written as of June 30, 2026sNDA for mitapivat granted FDA Priority Review in sickle cell disease with PDUFA goal date of November 1, 2026Diversified and expanded late-stage pipeline with licensing of cevidoplenib for immune thrombocytopen

In July 2026, Agios Pharmaceuticals reported topline Phase 2 results for tebapivat in sickle cell disease, showing hemoglobin and hemolysis improvements but insufficient differentiation versus placebo, and consequently decided to discontinue tebapivat’s development for this use. At the same time, Agios highlighted that the FDA had already accepted its supplemental New Drug Application for mitapivat in sickle cell disease under Priority Review, keeping a PK activator path in this indication...

Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agios Pharmaceuticals dropped its next-generation sickle cell drug Tuesday after a failed Phase 2 study. Agios stock tumbled.

This deals another blow to tebapivat’s development prospects following its May 2026 termination in MDS due to efficacy concerns.

The biotech firm said it will discontinue development of its therapy for sickle cell disease following the outcome of a Phase 2 trial.

Stock drops after development setbackAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) shares fell 14% on Tuesday after the company announced it will discontinue development of tebapivat for sickle cell disease following results from a Phase 2 clinical trial.

The study failure costs Agios a chance to one-up Novo Nordisk and represents yet another setback in a disease that’s frustrated drugmakers of late.

Hemoglobin response rates for tebapivat, a PK activator, were consistent with the class of medicine, but Phase 2 results did not establish a differentiated profile to support continued development in sickle cell diseaseSafety and tolerability of tebapivat were consistent with prior sickle cell disease trialssNDA for mitapivat, company’s foundational PK activator, is under FDA Priority Review in sickle cell disease; PDUFA goal date is November 1, 2026 CAMBRIDGE, Mass., July 21, 2026 (GLOBE NEWSWI